Lisata Therapeutics (LSTA) Stock Price, News & Analysis

Company Overview

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

Key Stats

• Today's Range: $2.60 to $2.86
• 50-Day Range: $2.10 to $2.94
• 52-Week Range: $1.87 to $4.20
• Volume: 16,914 shs
• Average Volume: 27,068 shs
• Market Capitalization: $22.76 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $15.00
• Consensus Rating: Buy

Lisata Therapeutics Stock Analysis - MarketRank™

Lisata Therapeutics scored higher than 48% of companies evaluated by MarketBeat, and ranked 555th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Lisata Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Lisata Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Lisata Therapeutics are expected to grow in the coming year, from ($2.66) to ($2.36) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Lisata Therapeutics is -1.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Lisata Therapeutics is -1.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Lisata Therapeutics has a P/B Ratio of 0.76. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.46% of the float of Lisata Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Lisata Therapeutics has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Lisata Therapeutics has recently increased by 8.45%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Lisata Therapeutics does not currently pay a dividend.

Dividend Growth

Lisata Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.46% of the float of Lisata Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Lisata Therapeutics has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Lisata Therapeutics has recently increased by 8.45%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.4 / 5
• News Sentiment: N/A

News Sentiment

Lisata Therapeutics has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Lisata Therapeutics this week, compared to 2 articles on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Lisata Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 9.60% of the stock of Lisata Therapeutics is held by insiders.

Percentage Held by Institutions

Only 8.94% of the stock of Lisata Therapeutics is held by institutions.

LSTA Stock Analysis - Frequently Asked Questions

How have LSTA shares performed this year?

Lisata Therapeutics' stock was trading at $2.98 at the beginning of 2025. Since then, LSTA stock has decreased by 11.4% and is now trading at $2.64.

How were Lisata Therapeutics' earnings last quarter?

Lisata Therapeutics, Inc. (NASDAQ:LSTA) issued its quarterly earnings data on Thursday, May, 8th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.53) by $0.02.
Read the conference call transcript.

How do I buy shares of Lisata Therapeutics?

Shares of LSTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Lisata Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Lisata Therapeutics investors own include PayPal (PYPL), JD.com (JD), NIO (NIO), Construction Partners (ROAD), Sunrun (RUN), ASE Technology (ASX) and Coinbase Global (COIN).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 7/03/2025
• Next Earnings (Estimated): 8/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:LSTA
• CIK: 320017
• Web: www.caladrius.com
• Phone: (908) 842-0100
• Fax: 646-514-7787
• Employees: 30
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $15.00
• High Stock Price Target: $15.00
• Low Stock Price Target: $15.00
• Potential Upside/Downside: +468.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.30)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$19.99 million
• Net Margins: N/A
• Pretax Margin: -2,027.00%
• Return on Equity: -61.37%
• Return on Assets: -53.35%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.52
• Quick Ratio: 7.52

Sales & Book Value

• Annual Sales: $1 million
• Price / Sales: 22.76
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.49 per share
• Price / Book: 0.76

Miscellaneous

• Outstanding Shares: 8,620,000
• Free Float: 7,789,000
• Market Cap: $22.76 million
• Optionable: Not Optionable
• Beta: 1.03